William Looney

Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry

Pharm Exec speaks with Spanish-born Belén Garijo, CEO of Merck KGaA, Darmstadt, Germany’s healthcare business, who shares her steady-eyed approach in transforming a traditional pharma unit focused on small molecules for chronic disease to a high-tech specialty producer of immunotherapy drugs for rare cancers.

In a continent marked by stark differences in governance, growth and market potential, the best bets must be pursued off script.

Pharm Exec sits down with veteran journalist Paula Apsell, the driving force behind the long-running PBS science series NOVA. Apsell offers straightforward advice to the biopharma industry: make your business a business of inspiration, where the return is measured in passion-and the sheer, simple pleasure of finding things out.

Despite Big Pharma's success in translating discovery research into products with proven clinical value, the industry continues to struggle in positioning medical research to the public as a distinctive force for good.

The influx of treatment breakthroughs and expanding science has not silenced the debate over the productivity of biopharma's R&D model, and the looming challenges for R&D decision-makers.